Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (701-710 of 993) with videos related to

Pageof 100
Sort By:
The New England Journal of Medicine|June 1, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate CancerNeeraj Agarwal, Nobuaki Matsubara, Arun A Azad, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialistsSebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
International Urology and Nephrology|May 4, 2022
Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicityFrancesco Chierigo, Marco Borghesi, Christoph Würnschimmel, et al.
European Urology|April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS StudyFred Saad, Maha H A Hussain, Bertrand Tombal, et al.
Urology|February 28, 2012
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experienceRoss J Mason, Wassim Kassouf, David G Bell, et al.
Urologic Oncology|December 3, 2014
The burden of skeletal-related events in patients with prostate cancer and bone metastasisFlorian Roghmann, Carina Antczak, Rana R McKay, et al.
The Prostate|February 21, 2022
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groupsBenedikt Hoeh, Christoph Würnschimmel, Rocco Simone Flammia, et al.
The Prostate|February 21, 2022
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patientsBenedikt Hoeh, Rocco S Flammia, Lukas Hohenhorst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS TrialMaha Hussain, Bertrand Tombal, Fred Saad, et al.
European Urology Oncology|April 6, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel TrialFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
Pageof 100

Showing results (701-710 of 993) with videos related to

Sort By:
Pageof 100
The New England Journal of Medicine|June 1, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate CancerNeeraj Agarwal, Nobuaki Matsubara, Arun A Azad, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialistsSebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
International Urology and Nephrology|May 4, 2022
Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicityFrancesco Chierigo, Marco Borghesi, Christoph Würnschimmel, et al.
European Urology|April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS StudyFred Saad, Maha H A Hussain, Bertrand Tombal, et al.
Urology|February 28, 2012
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experienceRoss J Mason, Wassim Kassouf, David G Bell, et al.
Urologic Oncology|December 3, 2014
The burden of skeletal-related events in patients with prostate cancer and bone metastasisFlorian Roghmann, Carina Antczak, Rana R McKay, et al.
The Prostate|February 21, 2022
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groupsBenedikt Hoeh, Christoph Würnschimmel, Rocco Simone Flammia, et al.
The Prostate|February 21, 2022
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patientsBenedikt Hoeh, Rocco S Flammia, Lukas Hohenhorst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS TrialMaha Hussain, Bertrand Tombal, Fred Saad, et al.
European Urology Oncology|April 6, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel TrialFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
Pageof 100